106 related articles for article (PubMed ID: 22563673)
21. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
22. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
23. DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer.
Amer NN; Khairat R; Hammad AM; Kamel MM
PLoS One; 2023; 18(5):e0284455. PubMed ID: 37200388
[TBL] [Abstract][Full Text] [Related]
24. [Clonal evolution in myelodysplastic syndromes].
Yoshida K
Rinsho Ketsueki; 2016 Jun; 57(6):723-9. PubMed ID: 27384851
[TBL] [Abstract][Full Text] [Related]
25. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
[TBL] [Abstract][Full Text] [Related]
26. CEBPA methylation and mutation in myelodysplastic syndrome.
Wen XM; Hu JB; Yang J; Qian W; Yao DM; Deng ZQ; Zhang YY; Zhu XW; Guo H; Lin J; Qian J
Med Oncol; 2015 Jul; 32(7):192. PubMed ID: 26025484
[TBL] [Abstract][Full Text] [Related]
27. DDX41: the poster child for familial AML.
Rio-Machin A; Fitzgibbon J
Blood; 2022 Aug; 140(7):667-669. PubMed ID: 35980681
[No Abstract] [Full Text] [Related]
28. [Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome].
Kokhno AV; Parovichnikova EN; Mikhaĭlova EA; Ustinova EN; Kaplanskaia IB; Dvirnyk VN; Ol'shanskaia IuV; Domracheva EV; Savchenko VG
Ter Arkh; 2010; 82(8):48-53. PubMed ID: 20873246
[TBL] [Abstract][Full Text] [Related]
29. The usefulness of mutational data on prognosis of myelodysplastic syndromes: alone or incorporated into the IPSS-R?
Li B; Liu J; Xu Z; Qin T; Shi Z; Song Z; Huang H; Fang L; Zhang H; Pan L; Hu N; Qu S; Zhang Y; Huang G; Xiao Z
Br J Haematol; 2018 Dec; 183(5):815-819. PubMed ID: 29193004
[No Abstract] [Full Text] [Related]
30. Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome.
Cheng YY; Chau D; Chan T; Gill H; Liang R; Kwong YL; Tse E
J Clin Pathol; 2010 Nov; 63(11):1008-11. PubMed ID: 20924036
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
[TBL] [Abstract][Full Text] [Related]
32. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.
Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J
Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418
[TBL] [Abstract][Full Text] [Related]
33. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
Johan MF; Bowen DT; Frew ME; Goodeve AC; Reilly JT
Br J Haematol; 2005 Apr; 129(1):60-5. PubMed ID: 15801956
[TBL] [Abstract][Full Text] [Related]
34. DDX41: here, there…and everywhere.
Reilly CR; Lane AA
Blood; 2023 Oct; 142(14):1177-1178. PubMed ID: 37796519
[No Abstract] [Full Text] [Related]
35. [Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review].
Chen J; Qu SQ; Qin TJ; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):857-860. PubMed ID: 33190445
[No Abstract] [Full Text] [Related]
36. Global increase in DNA methylation in patients with myelodysplastic syndrome.
Römermann D; Hasemeier B; Metzig K; Göhring G; Schlegelberger B; Länger F; Kreipe H; Lehmann U
Leukemia; 2008 Oct; 22(10):1954-6. PubMed ID: 18385753
[No Abstract] [Full Text] [Related]
37. [Sequential acquisition of mutations in myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
[TBL] [Abstract][Full Text] [Related]
38. [Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].
Zhang YZ; Zhao DD; Zhao WP; Zhao HF; Zhao ZG; Wang YF; Wu XX; Han XP; Da WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):108-12. PubMed ID: 22730659
[TBL] [Abstract][Full Text] [Related]
39. High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome.
Calvo X; Nomdedeu M; Navarro A; Tejero R; Costa D; Muñoz C; Pereira A; Peña O; Risueño RM; Monzó M; Esteve J; Nomdedeu B
Leuk Res; 2014 Aug; 38(8):874-81. PubMed ID: 24880536
[TBL] [Abstract][Full Text] [Related]
40. Successive relapses from donor and host cells in a patient with DEAD-box helicase 41 (DDX41)-associated myelodysplastic syndrome: The lessons to be learned.
Hirsch P; Bories D; Chapiro E; Nguyen-Khac F; Benusiglio PR; Norol F; Nguyen S
Br J Haematol; 2022 Nov; 199(4):623-626. PubMed ID: 36029113
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
